Teresa DeLuca
Teresa DeLuca's purchase track record
Teresa DeLuca has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/18/2026 | SGRY | $144K | pending | pending | — |
| 11/21/2022 | SGRY | $490K | +34.4% | +51.8% | +6.1% |
| 12/9/2021 | FRMM | $50K | -24.5% | -62.0% | -13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Forum Markets (FRMM) Sets FY2027 Sales Target, Launches AI JV. Forum Markets announced a projected sales range of $125 million to $175 million for fiscal year 2027. The company also created a joint venture called Forum Edge AI with Edge Node to develop AI-driven services. These moves show a focus on revenue growth and entry into the AI market, which could affect how the company is viewed by the market.
Transaction History
| SGRY | ▲ Buy | Open Market | 10,000 | $144K | 8/18/2026 | View on chart |
| LFST | ▼ Sell | Open Market | 7,500 | $95K | 8/14/2026 | View on chart |
| LFST | ▼ Sell | Open Market | 20,441 | $250K | 8/13/2026 | View on chart |
| LFST | ▲ Buy | Grant | 17,746 | $0 | 7/2/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 11,670 | $160K | 6/5/2026 | View on chart |
| SGRY | ▼ Sell | Open Market | 20,018 | $455K | 8/11/2025 | View on chart |
| LFST | ▲ Buy | Grant | 35,714 | $0 | 6/11/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 6,861 | $160K | 6/10/2025 | View on chart |
| LFST | ▲ Buy | Grant | 35,211 | $0 | 8/14/2024 | View on chart |
| LFST | ▲ Buy | Grant | 36,363 | $0 | 7/21/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 6,170 | $160K | 6/6/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 4,192 | $160K | 6/1/2023 | View on chart |
| SGRY | ▲ Buy | Open Market | 20,000 | $490K | 11/21/2022 | View on chart |
| SGRY | ▲ Buy | Grant | 4,030 | $160K | 5/20/2022 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,535 | $82K | 3/24/2022 | View on chart |
| FRMM | ▲ Buy | Open Market | 5,000 | $20K | 12/9/2021 | View on chart |
| FRMM | ▲ Buy | Open Market | 2,500 | $10K | 12/9/2021 | View on chart |
| FRMM | ▲ Buy | Open Market | 2,500 | $10K | 12/9/2021 | View on chart |
| FRMM | ▲ Buy | Open Market | 2,500 | $10K | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.